UK markets open in 4 hours 29 minutes
  • NIKKEI 225

    28,209.18
    +33.31 (+0.12%)
     
  • HANG SENG

    20,122.40
    -79.54 (-0.39%)
     
  • CRUDE OIL

    88.80
    -0.21 (-0.24%)
     
  • GOLD FUTURES

    1,790.60
    -0.60 (-0.03%)
     
  • DOW

    32,803.47
    +76.67 (+0.23%)
     
  • BTC-GBP

    19,258.38
    +152.23 (+0.80%)
     
  • CMC Crypto 200

    541.00
    +5.77 (+1.08%)
     
  • ^IXIC

    12,657.55
    -63.04 (-0.50%)
     
  • ^FTAS

    4,111.51
    -6.81 (-0.17%)
     

BB Biotech AG publishes its interim report

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BB BIOTECH AG / Key word(s): Interim Report
BB Biotech AG publishes its interim report

22-Jul-2022 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Ad hoc announcement pursuant to Art. 53 LR

July 22, 2022

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2022, which covers the results of its business activities for the first six months of 2022.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended June 30, 2022 amounted to CHF 533 mn (profit of CHF 349 mn in H1 2021). In the second quarter a loss of CHF 233 mn (profit of CHF 129 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG’s interim report as at June 30, 2022 is available under report.bbbiotech.ch/Q222 or www.bbbiotech.com.

 

For further information:

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

 

www.bbbiotech.com

Company profile 
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss, German and Italian stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.

22-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

BB BIOTECH AG

Schwertstrasse 6

8200 Schaffhausen

Switzerland

Phone:

+41 52 624 08 45

E-mail:

info@bbbiotech.com

Internet:

www.bbbiotech.ch

ISIN:

CH0038389992

WKN:

A0NFN3

Listed:

Regulated Market in Frankfurt (Prime Standard); Mailand, SIX

EQS News ID:

1403199


 

End of Announcement

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting